Ajmaline in WPW syndrome: an electrophysiologic study

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Wolff-Parkinson-White (WPW) syndrome is characterized by recurrent paroxysmal tachyarrhythmia due to an accessory pathway.
• Electrophysiological studies are crucial for diagnosing WPW syndrome and understanding accessory pathway function.

Purpose of the Study:

• To evaluate the efficacy and safety of ajmaline in blocking the accessory pathway (bundle of Kent) in WPW syndrome patients.
• To assess ajmaline's effectiveness in terminating and preventing tachyarrhythmias associated with WPW syndrome.

Main Methods:

• Electrophysiological studies were performed on six WPW syndrome patients, including basal parameters and rapid pacing.
• A single intravenous bolus of 50 mg ajmaline was administered.
• Long-term oral ajmaline therapy was assessed for arrhythmia prevention.

Main Results:

• Ajmaline effectively blocked the bundle of Kent within 30 seconds in all patients, with effects lasting 15-60 minutes.
• Significant prolongation of the HV interval and QRS complex normalization were observed.
• Ajmaline successfully terminated narrow and broad QRS tachycardias in treated patients.

Conclusions:

• Ajmaline is a safe and effective drug for acute and long-term management of WPW syndrome.
• The drug specifically targets and blocks the accessory pathway, offering rapid and sustained arrhythmia control.